Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
Ye Bi,1 Robert J Lee,1,2 Xinyu Wang,1 Yating Sun,1 Mengqiao Wang,1 Lianlian Li,1 Chenliang Li,1 Jing Xie,1 Lesheng Teng1 1School of Life Sciences, Jilin University, Changchun, Jilin, People’s Republic of China; 2Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Co...
Guardado en:
Autores principales: | Bi Y, Lee RJ, Wang X, Sun Y, Wang M, Li L, Li C, Xie J, Teng L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8db0d6001d8744e98dbbf27ac3c0593f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
por: Wu C, et al.
Publicado: (2018) -
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
por: Xing J, et al.
Publicado: (2019) -
Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes
por: Jin M, et al.
Publicado: (2018) -
Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7
por: Bi YZ, et al.
Publicado: (2016) -
Anti-EpCAM functionalized graphene oxide vector for tumor targeted siRNA delivery and cancer therapy
por: Si Chen, et al.
Publicado: (2021)